Norwegian life-sciences group Lifecare AS plans to begin trading today on the Merkur Market under the ticker symbol ‘LIFE-ME’. The company is developing an implantable glucose sensor designed for people living with diabetes. Get the full story at our sister site, Drug Delivery Business News.
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Companion Medical wins FDA nod for Android version of smart pen app
Companion Medical said today that it won FDA clearance for the Android version of its InPen app. The company’s InPen system consists of a smart insulin injection pen that connects with an integrated diabetes management app. Companion Medical expects to release the app for Android users by the fourth quarter of this year. Get the full […]
Insulet’s Omnipod nabs preferred insulin pump status in British Columbia
Insulet (NSDQ:PODD) said today that its Omnipod device was selected as the preferred insulin pump in British Columbia, Canada under the province’s expanded PharmaCare insulin pump program. According to the terms of the program, any eligible individual who requests an initial or replacement insulin pump will receive coverage for the Billerica, Mass.-based company’s device. Get the […]
Insulet assumes direct commercial operations in Europe
Insulet (NSDQ:PODD) said today that it has assumed direct commercial operations in Europe for its Omnipod tubeless insulin pump. The Billerica, Mass.-based company first announced it would part ways with its former European distributor, Ypsomed, in July last year. Insulet has since established a team of more than 100 employees to take care of distributing and selling its […]
Senseonics closes $150m public offering
Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds. The Germantown, Md.-based company plans to use its newly-acquired funds to support the commercialization of its implantable continuous glucose monitoring system, Eversense. Get the full story at our sister site, Drug Delivery Business News.
Medtronic launches outcomes-based reimbursement program for MiniMed 670G system
Medtronic (NYSE:MDT) today launched an outcomes-based reimbursement program for its MiniMed 670G automated insulin delivery system. As part of its ‘MiniMed 670G Performance Guarantee Program,’ the medtech giant will dole out flat-fee reimbursements of up to $25,000 per pump over four years for diabetes-related inpatient hospitalization and ER admissions. Get the full story at our sister […]
Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech
Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device. The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults using […]
Medtronic, IBM Watson Health launch AI-powered diabetes management app
Medtronic (NYSE:MDT), in partnership with IBM Watson Health, this week announced commercial availability of its AI-powered Sugar.IQ diabetes management app. Using artificial intelligence, the Sugar.IQ app evaluates how a user’s blood sugar levels respond to variables such as food intake, insulin dosing and other daily routines. Get the full story at our sister site, Drug Delivery Business […]
Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump
Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Get the full story at our sister site, Drug Delivery Business News.
One Drop launches blood glucose prediction, decision support features
One Drop this week launched blood glucose prediction and automated decision support features for its mobile app designed to help people manage their diabetes. The company said that the new features will enable its mobile app to give blood glucose predictions up to 12 hours into the future and behavioral recommendations based on those forecasts. Get […]
Senseonics prices $130m public offering
On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock. The offering, which is slated to close on June 28, also includes a 30-day option for underwriters to buy additional shares of common stock worth up to $19.5 million. Get […]